Levels of circulating cell-free DNA can potentially be used as a biomarker for assessing disease activity and monitoring treatment effectiveness in patients with systemic lupus erythematosus (SLE), a study shows.
The study, “High levels of circulating cell free DNA are a biomarker of active SLE,” was published in the European Journal of Clinical Investigation.
Recent studies have shown that SLE patients have higher levels of circulating cfDNA than healthy individuals.
For full article please click here.
